Sonidegib (diphosphate)

SKU HY-16582-10 mg Category Tags , ,

$55$242

Products Details

Product Description

– Sonidegib diphosphate (Erismodegib diphosphate) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].

Web ID

– HY-16582

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C26H32F3N3O11P2

Citations

– J Genet Genomics. 2018 May 20;45(5):237-246.|Nat Med. 2018 Nov;24(11):1752-1761. |Patent. US20180263995A1.|bioRxiv. 2023 Nov 6.|Cell Physiol Biochem. 2018;47(4):1352-1364.

References

– [1]Pan S, et al. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett. 2010 Mar 16;1(3):130-4.|[2]Irvine DA, et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci Rep. 2016 May 9;6:25476.

CAS Number

– 1218778-77-8

Molecular Weight

– 681.49

Compound Purity

– 99.73

SMILES

– O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4.O=P(O)(O)O.O=P(O)(O)O

Clinical Information

– Launched

Research Area

– Cancer

Solubility

– DMSO : 100 mg/mL (ultrasonic)|H2O : 0.25 mg/mL (ultrasonic)

Target

– Smo

Pathway

– Stem Cell/Wnt

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=